Traders purchased shares of Gilead Sciences Inc. (NASDAQ:GILD) on weakness during trading hours on Thursday. $174.92 million flowed into the stock on the tick-up and $112.68 million flowed out of the stock on the tick-down, for a money net flow of $62.24 million into the stock. Of all companies tracked, Gilead Sciences had the 3rd highest net in-flow for the day. Gilead Sciences traded down ($0.11) for the day and closed at $80.59

A number of analysts have recently weighed in on GILD shares. Morgan Stanley restated a “hold” rating and issued a $103.00 target price on shares of Gilead Sciences in a research note on Wednesday, June 15th. Piper Jaffray Cos. set a $108.00 target price on Gilead Sciences and gave the company a “buy” rating in a research note on Monday. Jefferies Group restated a “hold” rating and issued a $97.00 target price on shares of Gilead Sciences in a research note on Friday, July 15th. Maxim Group restated a “hold” rating on shares of Gilead Sciences in a research note on Sunday, July 10th. Finally, Vetr upgraded Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $105.06 target price for the company in a research note on Monday, May 2nd. Ten investment analysts have rated the stock with a hold rating, sixteen have issued a buy rating and three have issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $107.37.

The company’s 50-day moving average price is $82.95 and its 200 day moving average price is $87.39. The stock has a market cap of $106.35 billion and a PE ratio of 7.07.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Monday, July 25th. The biopharmaceutical company reported $3.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.02 by $0.06. During the same quarter in the previous year, the company posted $3.15 EPS. The firm earned $7.78 billion during the quarter, compared to the consensus estimate of $7.80 billion. The firm’s revenue was down 5.7% on a year-over-year basis. On average, equities research analysts predict that Gilead Sciences Inc. will post $11.78 earnings per share for the current year.

The company also recently declared a quarterly dividend, which will be paid on Thursday, September 29th. Shareholders of record on Friday, September 16th will be issued a $0.47 dividend. The ex-dividend date of this dividend is Wednesday, September 14th. This represents a $1.88 annualized dividend and a yield of 2.33%.

In other news, CEO John F. Milligan sold 112,000 shares of the firm’s stock in a transaction that occurred on Monday, June 6th. The stock was sold at an average price of $86.94, for a total value of $9,737,280.00. Following the transaction, the chief executive officer now owns 1,170,963 shares in the company, valued at $101,803,523.22. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Paul Rutherford Carter sold 2,000 shares of the firm’s stock in a transaction that occurred on Wednesday, June 1st. The shares were sold at an average price of $87.02, for a total value of $174,040.00. Following the completion of the transaction, the executive vice president now owns 63,122 shares in the company, valued at approximately $5,492,876.44. The disclosure for this sale can be found here.

Several hedge funds and institutional investors recently bought and sold shares of the stock. Westbourne Investment Advisors Inc. raised its position in Gilead Sciences by 0.3% in the fourth quarter. Westbourne Investment Advisors Inc. now owns 43,521 shares of the biopharmaceutical company’s stock worth $4,404,000 after buying an additional 118 shares in the last quarter. Brave Asset Management Inc raised its position in Gilead Sciences by 0.6% in the fourth quarter. Brave Asset Management Inc now owns 24,430 shares of the biopharmaceutical company’s stock worth $2,472,000 after buying an additional 150 shares in the last quarter. Stack Financial Management Inc raised its position in Gilead Sciences by 0.3% in the fourth quarter. Stack Financial Management Inc now owns 69,386 shares of the biopharmaceutical company’s stock worth $7,021,000 after buying an additional 205 shares in the last quarter. Oarsman Capital Inc. raised its position in Gilead Sciences by 1.0% in the fourth quarter. Oarsman Capital Inc. now owns 21,341 shares of the biopharmaceutical company’s stock worth $2,159,000 after buying an additional 205 shares in the last quarter. Finally, Argent Trust Co raised its position in Gilead Sciences by 1.4% in the third quarter. Argent Trust Co now owns 16,015 shares of the biopharmaceutical company’s stock worth $1,572,000 after buying an additional 227 shares in the last quarter.

Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.